Abstract
Extrapyramidal movement disorders are common in chronic schizophrenia, and may be an intrinsic feature of the illness as well as related to antipsychotic drug treatment. Similar dysfunctions at illness onset may have implications for outcome, and for understanding the mechanisms of illness. The objectives were to examine the clinical correlates of pre-treatment movement disorders at first episode of psychosis, and determine associations with neuropsychological function and striatal structure. Never medicated subjects were recruited from consecutive admissions to Early Psychosis Programs with defined catchment areas in Hong Kong, China, and Halifax, Canada. Standardized clinical, neuropsychological and brain imaging assessments were carried out at baseline and following acute and long term treatment with typical or atypical antipsychotic drugs. At the Hong Kong site, we studied 84 subjects with first episode psychosis (n = 10 with EPS). At the Halifax site, we studied 40 subjects with first episode psychosis (n = 17 with EPS), and 23 healthy comparison subjects. Subjects with movement disorders prior to treatment (EPS+) had higher total PANSS scores at baseline (mean elevation 19.9% Hong Kong, P = 0.016; 14.7% Halifax, P = 0.049). In subjects treated with atypical antipsychotics (all Halifax), EPS+ status at baseline predicted more movement disorders at long term follow up (P = 0.0005). In both cohorts, EPS+ subjects had poorer acute symptomatic treatment response assessed with the PANSS (Hong Kong P = 0.005; Halifax P = 0.017). Neuropsychological impairment related to executive dysfunction appeared greater in a small sample of EPS+ subjects (Hong Kong, effect size 0.26–0.27, P < 0.05). Caudate volumes were 4.5% larger in EPS+ compared with EPS-subjects (Halifax P = 0.042), and correlations between striatal volumes and age were different in the EPS+ group. In conclusion, pre-treatment EPS is present in a substantial minority of subjects with first episode psychosis, appears to persist at long term follow up, and is associated with poorer response of symptoms to treatment. Selective impairment of executive function and striatal enlargement provides evidence of abnormalities of brain function and structure associated with this aspect of early psychosis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Torrey E F. Studies of individuals with schizophrenia never treated with antipsychotic medications: A review. Schizophr Res, 2002, 58: 101–115
Turner T. Rich and mad in Victorian England. Psychol Med, 1989, 19: 29–44
Fenton W S. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry, 2000, 61 (Suppl 4): 10–14
Rogers D. The motor disorders of severe psychiatric illness: A conflict of paradigms. Br J Psychiatry, 1985, 147: 221–232
Koning J P, Tenback D E, van Os J, et al. Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: A meta-analysis. Schizophr Bull, 2010, 36: 723–731
Koning J P, Kahn R S, Tenback D E, et al. Movement disorders in nonpsychotic siblings of patients with nonaffective psychosis. Psychiatry Res, 2011, 188: 133–137
Chan R C, Gottesman I I. Neurological soft signs as candidate endophenotypes for schizophrenia: A shooting star or a Northern star? Neurosci Biobehav Rev, 2008, 32: 957–971
Chan R C, Xu T, Heinrichs R W, et al. Neurological soft signs in schizophrenia: A meta-analysis. Schizophr Bull, 2010, 36: 1089–1104
Peralta V, Cuesta M J, Martinez-Larrea A, et al. Differentiating primary from secondary negative symptoms in schizophrenia: A study of neuroleptic-naive patients before and after treatment. Am J Psychiatry, 2000, 157: 1461–1466
Puri B K, Barnes T R E, Chapman M J, et al. Spontaneous dyskinesia in first episode schizophrenia. J Neurol Neurosurg Psychiatry, 1999, 66: 76–78
Gervin M, Browne S, Lane A, et al. Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: Baseline rate in a group of patients from an Irish catchment area. Am J Psychiatry, 1998, 155: 1202–1206
Kopala L C, Good K P, Fredrikson D, et al. Risperidone in first-episode schizophrenia: Improvement in symptoms and pre-existing extrapyramidal signs. Int J Psychiatry Clin Practice, 1998, 2: S19–S25
Fenn D S, Moussaoui D, Hoffman W F, et al. Movements in never-medicated schizophrenics: A preliminary study. Psychopharmacology, 1996, 123: 206–210
Chorfi M, Moussaoui D. Les schizophrènes jamais traités n’ont pas de mouvements anormaux type dyskinésie tardive. L’Encéphale, 1985, 9: 263–265
Caligiuri M P, Lohr J B, Jeste D V. Parkinsonism in neuroleptic-naive schizophrenic patients. Am J Psychiatry, 1993, 150: 1343–1348
Chatterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry, 1995, 152: 1724–1729
Honer W G, Kopala L C, Rabinowitz J. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. J Psychopharmacol, 2005, 19: 277–285
Peralta V, Cuesta M J. Neuromotor abnormalities in neurolepticnaive psychotic patients: Antecedents, clinical correlates, and prediction of treatment response. Compr Psychiatry, 2011, 52: 139–145
Bocti C, Black D N, Waddington J L. Dyskinesia in patients with schizophrenia never treated with antipsychotics: Conceptual and pathophysiological implications. In: Bedard M A, Agid Y, Chouinard S, et al., eds. Mental and Behavioral Dysfunction in Movement Disorders. Totawa, N.J.: Humana Press, 2003. 489–498
McCreadie R G, Srinivasan T N, Padmavati R, et al. Extrapyramidal symptoms in unmedicated schizophrenia. J Psychiatric Res, 2005, 39: 261–266
McCreadie R G, Thara R, Padmavati R, et al. Structural brain differences between never-treated patients with schizophrenia, with and without dyskinesia, and normal control subjects. Arch Gen Psychiatry, 2002, 59: 332–336
McCreadie R G, Padmavati R, Thara R, et al. Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up. Br J Psychiatry, 2002, 181: 135–137
McCreadie R G, Latha S, Thara R, et al. Poor memory, negative symptoms and abnormal movements in never-treated Indian patients with schizophrenia. Br J Psychiatry, 1997, 171: 360–363
Simpson G M, Angus J W S. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand, 1970, 10: 199–208
Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. (Publication ADM 76-338). Rockville Pike, MD: US Department of Health, Education, and Welfare, 1976
Chouinard G, Annable L, Ross-Chouinard A, et al. Ethopropazine and benztropine in neuroleptic-induced Parkinsonism. J Clin Psychiatry, 1979, 40: 147–152
Peralta V, Cuesta M J. Negative, parkinsonian, depressive and catatonic symptoms in schizophrenia: A conflict of paradigms revisited. Schizophr Res, 1999, 40: 245–253
Kay S, Fiszbein A, Opler L A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull, 1987, 13: 261–276
Wechsler D. Wechsler Memory Scale: Revised Manual. New York: Harcourt Brace Jovanovich, 1987
Nelson H E. A modified card sorting test sensitive to frontal lobe defects. Cortex, 1976, 12: 313–324
Lang D J, Kopala L C, Vandorpe R A, et al. An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone. Am J Psychiatry, 2001, 158: 625–631
Lang D J, Kopala L C, Vandorpe R A, et al. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia. Am J Psychiatry, 2004, 161: 1829–1836
Gunduz H, Wu H, Ashtari M, et al. Basal ganglia volumes in first-episode schizophrenia and healthy comparison subjects. Biol Psychiatry, 2002, 51: 801–808
Cortese L, Caligiuri M P, Malla A K, et al. Relationship of neuromotor disturbances to psychosis symptoms in first-episode neuroleptic-naive schizophrenia patients. Schizophr Res, 2005, 75: 65–75
Jager A D. Abnormal movements in first episode psychosis. Australas Psychiatry, 2000, 18: 38–41
Chakos M, Ma J, Alvir J, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry, 1996, 53: 313–319
Schröder J, Niethammer G, Geider F-J, et al. Neurological soft signs in schizophrenia. Schizophr Res, 1992, 6: 25–30
Whitty P, Clarke M, Browne S, et al. Prospective evaluation of neurological soft signs in first-episode schizophrenia in relation to psychopathology: State versus trait phenomena. Psychol Med, 2003, 33: 1479–1484
Kopala L C, Good K P, Honer W G. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: Response to low-dose risperidone. J Clin Psychopharmacol, 1997, 17: 308–313
Schröder J, Silvestri S, Bubeck B, et al. D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia. Biol Psychiatry, 1998, 43: 660–665
Waddington J L, Youssef H A. The lifetime outcome and involuntary movements of schizophrenia never treated with neuroleptic drugs. Br J Psychiatry, 1990, 156: 106–108
Pantelis C, Stuart G W, Nelson H E, et al. Spatial working memory deficits in schizophrenia: Relationship with tardive dyskinesia and negative symptoms. Am J Psychiatry, 2001, 158: 1276–1285
Quinn J, Meagher D, Murphy P, et al. Vulnerability to involuntary movements over a lifetime trajectory of schizophrenia approaches 100%, in association with executive (frontal) dysfunction. Schizophr Res, 2001, 49: 79–87
Meyer-Lindenberg A, Miletich R S, Kohn P D, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci, 2002, 5: 267–271
McGowan S, Lawrence A D, Sales T, et al. Presynaptic dopamine dysfunction in schizophrenia. Arch Gen Psychiatry, 2004, 61: 134–142
Meyer-Lindenberg A, Kohn P D, Kolachana B, et al. Midbrain dopamine and prefrontal function in humans: Interaction and modulation by COMT genotype. Nat Neurosci, 2005, 8: 828–834
Shihabuddin L, Buchsbaum M S, Hazlett E A, et al. Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task. Arch Gen Psychiatry, 1998, 55: 235–243
DeLisi L E, Hoff A L, Schwartz J E, et al. Brain morphology in first-episode schizophrenic-like psychotic patients: A quantitative magnetic resonance imaging study. Biol Psychiatry, 1991, 29: 159–175
Chakos M H, Lieberman J a, Bilder R M, et al. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry, 1994, 151: 1430–1436
Gur R E, Maany V, Mozley P D, et al. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry, 1998, 155: 1711–1717
Glenthoj A, Glenthoj B Y, Mackeprang T, et al. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Res, 2007, 154: 199–208
Crespo-Facorro B, Roiz-Santiáñez R, Pelayo-Terán J M, et al. Caudate nucleus volume and its clinical and cognitive correlations in first episode schizophrenia. Schizophr Res, 2007, 91: 87–96
Ballmaier M, Schlagenhauf F, Toga A W, et al. Regional patterns and clinical correlates of basal ganglia morphology in non-medicated schizophrenia. Schizophr Res, 2008, 106: 140–147
Keshevan M S, Rosenberg D, Sweeney J A, et al. Decreased caudate volume in neuroleptic-naive psychotic patients. Am J Psychiatry, 1998, 155: 774–778
Westmoreland Corson P, Nopoulos P, Miller D D, et al. Change in basal ganglia volume over 2 years in patients with schizophrenia: Typical versus atypical neuroleptics. Am J Psychiatry, 1999, 156: 1200–1204
Ebdrup B H, Glenthøj B, Rasmussen H, et al. Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. J Psychiatry Neurosci, 2010, 35: 95–104
Rajarethinam R, Upadhyaya A, Tsou P, et al. Caudate volume in offspring of patients with schizophrenia. Br J Psychiatry, 2007, 191: 258–259
Eliez S, Barnea-Goraly N, Schmitt E J, et al. Increased basal ganglia volumes in velo-cardio-facial syndrome (deletion 22q11.2). Biol Psychiatry, 2002, 52: 68–70
Kates W R, Burnette C P, Bessette B A, et al. Frontal and caudate alterations in velocardiofacial syndrome (deletion at chromosome 22q11.2). J Child Neurol, 2004, 19: 337–342
Campbell L E, Daly E, Toal F, et al. Brain and behaviour in children with 22q11.2 deletion syndrome: A volumetric and voxel-based morphometry MRI study. Brain, 2006, 129: 1218–1228
Wilson J M, Levey A I, Bergeron C, et al. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol, 1996, 40: 428–439
Moszczynska A, Fitzmaurice P, Ang L, et al. Why is Parkinsonism not a feature of human methamphetamine users? Brain, 2004, 127: 363–370
Chang L, Cloak C, Patterson K, et al. Enlarged striatum in abstinent methamphetamine abusers: A possible compensatory response. Biol Psychiatry, 2005, 57: 967–974
Jacobsen L K, Giedd J N, Gottschalk C, et al. Quantitative morphology of the caudate and putamen in patients with cocaine dependence. Am J Psychiatry, 2001, 158: 486–489
Keshavan M S, Bagwell W W, Haas G L, et al. Changes in caudate volume with neuroleptic treatment. Lancet, 1994, 344: 1434
Chakos M H, Lieberman J A, Alvir J, et al. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet, 1995, 345: 456–457
Scheepers F E, de Wied C C, Pol H E, et al. The effects of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. Neuropsychopharmacol, 2001, 24: 47–54
Frazier J A, Giedd J N, Kaysen D, et al. Childhood-onset schizophrenia: Brain MRI rescan after 2 years of clozapine maintenance treatment. Am J Psychiatry, 1996, 153: 564–566
Hietala J, Syvalahti E, Vilkman H, et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res, 1999, 35: 41–50
Hietala J, Syvalahti E, Vuorio K, et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet, 1995, 346: 1130–1131
Reith J, Benkelfat C, Sherwin A, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA, 1994, 91: 11651–11654
Grunder G, Vernaleken I, Muller M J, et al. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacol, 2003, 28: 787–794
Kish S J, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. New Engl J Med, 1988, 318: 876–880
Chen E, Hui C, Lam M, et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: Randomised controlled trial. BMJ, 2010, 341: c4024
Smith G N, MacEwan G W, Kopala L C, et al. Prenatal tobacco exposure and obstetrical, developmental and substance use problems in first-episode psychosis. Schizophr Res, 2010, 119: 271–272
Smith G N, Wong H, MacEwan G W, et al. Predictors of starting to smoke cigarettes in patients with first episode psychosis. Schizophr Res, 2009, 108: 258–264
McCreadie R G, Thara R, Srinivasan T N, et al. Spontaneous dyskinesia in first-degree relatives of chronically ill, never-treated people with schizophrenia. Br J Psychiatry, 2003, 183: 45–49
Levitt J J, McCarley R W, Dickey C C, et al. MRI study of caudate nucleus volume and its cognitive correlates in neuroleptic-naive patients with schizotypal personality disorder. Am J Psychiatry, 2002, 159: 1190–1197
Shihabuddin L, Buchsbaum M S, Hazlett E A, et al. Striatal size and relative glucose metabolic rate in schizotypal personality disorder and schizophrenia. Arch Gen Psychiatry, 2001, 58: 877–884
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Honer, W.G., Lang, D.J., Kopala, L.C. et al. First episode psychosis with extrapyramidal signs prior to antipsychotic drug treatment. Chin. Sci. Bull. 56, 3361–3371 (2011). https://doi.org/10.1007/s11434-011-4738-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11434-011-4738-y